Simona Carnio
Overview
Explore the profile of Simona Carnio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Antonuzzo A, Gonella S, Blasi L, Carnio S, Franzese C, Marano L, et al.
Healthcare (Basel)
. 2025 Feb;
13(3).
PMID: 39942401
Cancer pain is prevalent across all stages of the disease, significantly impacting patients' lives. Despite the availability of guidelines, its assessment and management remain suboptimal in many clinical settings. This...
2.
Bertaglia V, Petrelli F, Dottorini L, Carnio S, Morelli A, Nepote A, et al.
Semin Oncol
. 2025 Jan;
52(1):14-18.
PMID: 39743384
Background: Small-cell lung cancer (SCLC) accounts for 10%-15% of all lung cancers. At diagnosis, nearly two thirds of patients with SCLC have extensive stage (ES), with a median overall survival...
3.
Nepote A, Poletto S, Bertaglia V, Carnio S, Piumatti C, Lanzetta C, et al.
Crit Rev Oncol Hematol
. 2024 Nov;
205:104540.
PMID: 39486561
Single-agent osimertinib has improved outcomes in EGFR-mutated lung cancer patients with brain metastases (BMs), but still, 40 % of them will experience an intracranial progression. We performed a systematic review...
4.
Celio L, Cortinovis D, Cogoni A, Cavanna L, Martelli O, Carnio S, et al.
Sci Rep
. 2023 Jan;
13(1):1257.
PMID: 36690734
We demonstrated the non-inferiority of a dexamethasone (DEX)-sparing (single-dose) regimen with NEPA, a netupitant/palonosetron fixed combination, for preventing chemotherapy-induced nausea and vomiting (CINV) caused by cisplatin. This pre-planned exploratory analysis...
5.
Caccialanza R, Cereda E, Agustoni F, Klersy C, Casirati A, Montagna E, et al.
BMC Cancer
. 2022 Nov;
22(1):1212.
PMID: 36434615
Background: Nutritional support, including nutritional counseling and oral nutritional supplements (ONS), has been recommended as a first-line strategy in patients with non-small cell lung cancer (NSCLC). Evidence on the efficacy...
6.
Mariniello A, Tabbo F, Indellicati D, Tesauro M, Rezmives N, Reale M, et al.
Cells
. 2022 Oct;
11(20).
PMID: 36291098
Background: Lung cancer (LC) tissue for immunological characterization is often scarce. We explored and compared T cell characteristics between broncho-alveolar lavage from tumor affected (t-BAL) and contralateral lung (cl-BAL), with...
7.
Celio L, Cortinovis D, Cogoni A, Cavanna L, Martelli O, Carnio S, et al.
BMC Cancer
. 2022 Aug;
22(1):915.
PMID: 35999527
Background: The non-inferiority of dexamethasone (DEX) on day 1, with or without low-dose DEX on days 2 and 3, combined with oral NEPA (netupitant/palonosetron), compared with the guideline-consistent use of...
8.
Mariniello A, Righi L, Morrone A, Carnio S, Bironzo P
Tumori
. 2022 Mar;
108(6):NP15-NP19.
PMID: 35277092
Introduction: In non-small cell lung cancer (NSCLC) histologic transformation upon immune checkpoint inhibitors (ICI) is rare. Case Presentation: We described the case of a patient with early-stage lung adenocarcinoma who...
9.
Tagliamento M, Bironzo P, Curcio H, De Luca E, Pignataro D, Rapetti S, et al.
Crit Rev Oncol Hematol
. 2022 Feb;
172:103639.
PMID: 35192932
Introduction: Advanced stage malignant mesothelioma (asMM) patients have poor prognosis. Several trials investigated the role of programmed cell death protein-1 (PD-1) and its ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs)...
10.
Passaro A, Novello S, Giannarelli D, Bria E, Galetta D, Gelibter A, et al.
Cancers (Basel)
. 2021 Jul;
13(12).
PMID: 34208253
Background: Pembrolizumab is approved in monotherapy for the first-line (1L) of advanced or metastatic NSCLC patients with high PD-L1 (≥50%). Despite a proportion of patients achieve long-term survival, about one-third...